Search by Drug Name or NDC
NDC 00832-0285-00 Bexarotene 75 mg/1 Details
Bexarotene 75 mg/1
Bexarotene is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Upsher-Smith Laboratories, Inc.. The primary component is BEXAROTENE.
MedlinePlus Drug Summary
Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications called retinoids. It works by stopping the growth of cancer cells.
Related Packages: 00832-0285-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Bexarotene
Product Information
| NDC | 00832-0285 |
|---|---|
| Product ID | 0832-0285_0392c67b-a83c-4e6c-95d6-09604953652d |
| Associated GPIs | 21708220000120 |
| GCN Sequence Number | 044269 |
| GCN Sequence Number Description | bexarotene CAPSULE 75 MG ORAL |
| HIC3 | V1N |
| HIC3 Description | ANP - SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR) |
| GCN | 92373 |
| HICL Sequence Number | 020832 |
| HICL Sequence Number Description | BEXAROTENE |
| Brand/Generic | Generic |
| Proprietary Name | Bexarotene |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Bexarotene |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 75 |
| Active Ingredient Units | mg/1 |
| Substance Name | BEXAROTENE |
| Labeler Name | Upsher-Smith Laboratories, Inc. |
| Pharmaceutical Class | Retinoid [EPC], Retinoids [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA209886 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00832-0285-00 (00832028500)
| NDC Package Code | 0832-0285-00 |
|---|---|
| Billing NDC | 00832028500 |
| Package | 100 CAPSULE in 1 BOTTLE (0832-0285-00) |
| Marketing Start Date | 2018-07-25 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |